FTSE MIB
34.657,35 +318,03 (+0,93%) Dow Jones
39.512,84 +125,08 (+0,32%) Nasdaq
16.340,87 -5,40 (-0,03%) Nikkei 225
38.229,11 +155,13 (+0,41%) Petrolio
78,20 -1,06 (-1,34%) Bitcoin EUR
56.481,09 -1.843,81 (-3,16%)
Cyclacel Pharmaceuticals, Inc. (CYCC)
Dopo ore:
| Chiusura precedente | 2,3100 |
| Aperto | 2,1575 |
| Denaro | 2,2600 x 100 |
| Lettera | 2,3100 x 100 |
| Min-Max giorno | 2,1568 - 2,2991 |
| Intervallo di 52 settimane | 1,3000 - 13,2000 |
| Volume | |
| Media Volume | 792.707 |
| Capitalizzazione | 3,38M |
| Beta (5 anni mensile) | 0,55 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -26,7500 |
| Prossima data utili | 14 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 11,00 |
GlobeNewswireCyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update
- Key Catalysts ahead with Multiple Value Generating Readouts-- Expects to Release Phase 1/2 Data with Oral Fadraciclib -- Signals of Single-agent Efficacy with Oral Plogosertib -- Management to Host Conference Call at 4:30 pm EDT Today- BERKELEY HEIGHTS, N.J., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical leader in cell cycle checkpoint control developing innovative medicines based on cancer cell
- GlobeNewswire
Cyclacel Pharmaceuticals to Release Second Quarter 2023 Financial Results
BERKELEY HEIGHTS, N.J., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce second quarter 2023 financial results on Wednesday August 9, 2023. The Company will host a conference call and live webcast at 4:30 p.m. Eastern Daylight Time on the same day. Conference call information: Call: (800) 225-9448 / international call:
